Preclinical assessment of APL-030, a selective and orally bioavailable inhibitor of the integrated stress response regulator GCN2 with activity against acute myeloid leukemia

APL-030 - Apollo Therap

M. Roman-Trufero 1; G. Whitlock 2; M. Fuchter 3; M. Jeyakumar 3; P. Chaida 4; S. Herzog 4; A. Zebisch 4; R. Butt 5; H. W. Auner 1; N. Clemo5

Mar 6, 2024